In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment.
Prof. Catto shares details on the rationale and design of the THOR-2 cohort 1 study, the results he presented at ESMO 2023, and some important take-home messages.
For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.